Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| PULM | Pulmatrix | $2.39 | -$1.33 | -35.75% | 200.1K | $14M | $2.32$10.40 |
| RKLZ | Tidal Trust II - Defiance Daily Target 2x Short Rklb ETF | $5.51 | -$2.77 | -33.45% | 4.9M | - | $5.37$25.51 |
| FCUV | Focus Universal | $2.03 | -$0.88 | -30.24% | 151.2K | $24M | $1.80$10.90 |
| GALT | Galectin Therapeutics | $4.30 | -$1.86 | -30.19% | 3.7M | $397M | $0.73$7.13 |
| AFJK | Aimei Health Technology | $37.88 | -$14.35 | -27.47% | 116.9K | $320M | $6.75$98.15 |
| ALT | Altimmune | $3.86 | -$1.19 | -23.56% | 569.5K | $527M | $2.90$8.75 |
| SAVA | Cassava Sciences | $2.19 | -$0.66 | -23.16% | 4.5M | $138M | $1.15$4.98 |
| NVA | Nova Minerals | $6.68 | -$1.46 | -17.95% | 2.2M | $282M | $1.68$16.28 |
| EVAX | Evaxion A/s | $4.74 | -$1.01 | -17.57% | 366.2K | $36M | $1.20$12.15 |
Related Articles
Featured Article
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Adam Spatacco|Aug 9, 2024
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space.
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
Alex Carchidi|Jul 20, 2024
At least one of the pair has a credible shot at finding a home in the market.
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Alex Carchidi|Jul 10, 2024
Both competitors have promising lead programs, and enough cash, too.
Advertisement
3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
Alex Carchidi|Jun 30, 2024
While their share prices have traveled different paths recently, the similarity between the two companies is striking.
If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
Alex Carchidi|Jun 29, 2024
The market for weight loss medicines keeps getting hotter and hotter.
Is There Any Hope for Cassava Sciences Stock?
Alex Carchidi|Feb 3, 2024
Battered by controversy, this company will need to show real results to prosper.
1 Big Red Flag to Fear When a Stock Is Down
Alex Carchidi|Oct 31, 2023
Playing the blame game does not make for an effective turnaround strategy.
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
Keith Speights|Mar 22, 2023
It's not the end of the story for this once high-flying biotech stock.
3 Big Reasons to Sell Cassava Sciences Stock Right Now
Alex Carchidi|Feb 1, 2023
It isn't about running out of money, but it's still laden with risk.
My 3 Top Biotech Stock Picks for 2023
George Budwell, PhD|Nov 22, 2022
Biotech stocks are set to shine in 2023.
